G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
G970R‐CFTR
Mutation (c.2908G>C) Results Predominantly in a Splicing Defect
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-06
DOI
10.1111/cts.12927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Two CFTR mutations within codon 970 differently impact on the chloride channel functionality
- (2019) Felice Amato et al. HUMAN MUTATION
- Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study
- (2019) Jerry A. Nick et al. Journal of Cystic Fibrosis
- Ivacaftor treatment of cystic fibrosis in children aged 12 to
- (2018) Margaret Rosenfeld et al. Lancet Respiratory Medicine
- From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
- (2016) Gudio Veit et al. MOLECULAR BIOLOGY OF THE CELL
- Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
- (2016) Johanna F. Dekkers et al. Science Translational Medicine
- StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
- (2015) Mihaela Pertea et al. NATURE BIOTECHNOLOGY
- Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial
- (2015) Richard B Moss et al. Lancet Respiratory Medicine
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
- (2014) Kris De Boeck et al. Journal of Cystic Fibrosis
- Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping
- (2014) Paula J P de Vree et al. NATURE BIOTECHNOLOGY
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551DMutation
- (2013) Jane C. Davies et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene
- (2013) Patrick R Sosnay et al. NATURE GENETICS
- A functional CFTR assay using primary cystic fibrosis intestinal organoids
- (2013) Johanna F Dekkers et al. NATURE MEDICINE
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Ivacaftor potentiation of multiple CFTR channels with gating mutations
- (2012) Haihui Yu et al. Journal of Cystic Fibrosis
- Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium
- (2011) Toshiro Sato et al. GASTROENTEROLOGY
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation
- (2010) Frank J. Accurso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation-Specific Potency and Efficacy of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Potentiators
- (2009) A. Caputo et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Cystic fibrosis
- (2009) Brian P O'Sullivan et al. LANCET
- Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
- (2008) C. Castellani et al. Journal of Cystic Fibrosis
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started